Telmisartan prevents aneurysm progression in the rat by inhibiting proteolysis, apoptosis and inflammation

Journal of Hypertension

Volumn 26, Issue 12, 2008, Pages 2361-2373

  Kaschina, Elena ^a   Schrader, Felix ^a   Sommerfeld, Manuela ^a   Kemnitz, Ulrich Rudolf ^a   Grzesiak, Aleksandra ^a   Krikov, Maxim ^a   Unger, Thomas ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Aneurysm; Aorta; Telmisartan

Indexed keywords

CASPASE 3; CATHEPSIN D; ELASTASE; FAS LIGAND; HYDRALAZINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PROTEIN P53; STROMELYSIN; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOIC ACID DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL AORTA ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; HEMODYNAMIC PARAMETERS; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE; ABDOMINAL AORTA; ANIMAL; BLOOD PRESSURE; BROWN NORWAY RAT; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN DENATURATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; APOPTOSIS; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CATHEPSIN D; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYDRALAZINE; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 3; NF-KAPPA B; PROTEIN DENATURATION; RATS; RATS, INBRED BN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 59849112584     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328313e547     Document Type: Article

References (44)

1. Curci JA, Thompson RW. Adaptive cellular immunity in aortic aneurysms: cause, consequence, or context? J Clin Invest 2004; 114:168-171.
2. Daugherty A, Cassis LA. Mechanisms of abdominal aortic aneurysm formation. Curr Atheroscler Rep 2002; 4:222-227.
3. Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-de?cient mice. J Clin Invest 2000; 105:1605-1612.
4. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. In?ammation and angiotensin II. Int J Biochem Cell Biol 2003; 35:881- 900.
5. Graninger M, Reiter R, Drucker C, Minar E, Jilma B. Angiotensin receptor blockade decreases markers of vascular in?ammation. J Cardiovasc Pharmacol 2004; 44:335-339.
6. Ruiz-Ortega M, Ruperez M, Esteban V, Egido J. Molecular mechanisms of angiotensin II-induced vascular injury. Curr Hypertens Rep 2003; 5:73- 79.
7. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20:645-651.
8. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept 2000; 93:65-77.
9. Chase A, Bond M, Crook MF, Newby AC. Role of NF-kB activation in metalloproteinase-1, -3 and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 2002; 22:765-771.
10. Yoon S, Tromp G, Vongpunsawad S, Ronkainen A, Juvonen T, Kuivaniemi H. Genetic analysis of MMP3, MMP9, and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun 1999; 265:563-568.
11. Silence J, Lupu F, Collen D, Lijnen HR. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP- 3) gene inactivation. Arterioscler Thromb Vasc Biol 2001; 21:1440-1445.
12. de Gasparo M, Catt KJ, Inagami T,Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52:415-472.
13. Schiffrin EL, Touyz RM. Multiple actions of angiotensin II in hypertension: bene?ts of AT1 receptor blockade. J Am Coll Cardiol 2003; 42:911-913.
14. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86:747-803.
15. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31:349-355.
16. Daugherty A, Manning MW, Cassis LA. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 2001; 134:865-870.
17. Steckelings UM, Rompe F, Artuc M, Hallberg A, Faendriks L, SchunckWH, et al. Angiotensin II and in?ammation: studies on AT1- and AT2-receptor coupled signalling using the novel nonpeptide AT2-receptor agonist compound 21. Hypertension 2006; 48 (Suppl):S766.
18. Liao S, Miralles M, Kelley BJ, Curci JA, Borhani M, Thompson RW. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001; 33:1057-1064.
19. Hackam DG, Thiruchelvam D, Redelmeier DA. Angiotensin converting enzyme inhibitors and aortic rupture: population based case control study. Lancet 2006; 368:659-665.
20. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 2006; 312:117-121.
21. Moran CS, McCann M, Karan M, Norman P, Ketheesan N, Golledge J. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation 2005; 111:3119-3125.
22. Lacourciere Y, Neutel JM, DavidaiG, Koval S. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Am J Hypertens 2006; 19:104-112.
23. Unger T, Kaschina E. Drug interactions with angiotensin receptor blockers: a comparison with other hypertensives. Drug Saf 2003; 26:707-720.
24. Anidjar S, Salzmann JL, Gentric D, Lagneau P, Camilleri JP, Michel JB. Elastase-induced experimental aneurysms in rats. Circulation 1990; 82:973-981.
25. Kaschina E, Stoll M, Sommerfeld M, Steckelings UM, Kreutz R, Unger T. Genetic kininogen de?ciency contributes to aortic aneurysm formation but not to atherosclerosis. Physiol Genomics 2004; 19:41-49.
26. Daugherty A, Cassis LA. Mouse models of abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2004; 24:429-434.
27. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006; 26:2605-2613.
28. Kaschina E, Scholz H, Sommerfeld M, Vosgerau U, Doerfel N, Kintscher U, et al. Activation of different proteolytic systems in human abdominal aortic aneurysms [abstract]. Hypertension 2005; 46 (Suppl 4):S915.
29. Tsunemi K, Takai S, Nishimoto M, Yuda A, Hasegawa S, Sawada Y, et al. Possible roles of angiotensin II-forming enzymes, angiotensin converting enzyme and chymase-like enzyme, in the human aneurysmal aorta. Hypertens Res 2002; 25:817-822.
30. Newman KM, Ogata Y, Malon AM, Irizarry E, Gandhi RH, Nagase H, et al. Identi?cation of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb 1994; 14:1315-1320.
31. Nakashima H, Aoki M, Miyake T, Kawasaki T, Iwai M, Jo N, et al. Inhibition of experimental abdominal aortic aneurysm in the rat by use of decoy oligodeoxynucleotides suppressing activity of nuclear factor kappaB and ets transcription factors. Circulation 2004; 109:132-138.
32. Tsukuba T, Okamoto K, Yasuda Y, MorikawaW, Nakanishi H, Yamamoto K. New functional aspects of cathepsin D and cathepsin E. Mol Cells 2000; 10:601-611.
33. Hamano K, Li TS, Takahashi M, Kobayashi T, Shirasawa B, Ito H, et al. Enhanced tumor necrosis factor-alpha expression in small sized abdominal aortic aneurysms. World J Surg 2003; 27:476-480.
34. Colonnello JS, Hance KA, Shames ML,Wyble CW, Ziporin SJ, Leidenfrost JE, et al. Transient exposure to elastase induces mouse aortic wall smooth muscle cell production of MCP-1 and RANTES during development of experimental aortic aneurysm. J Vasc Surg 2003; 38:138-146.
35. Wahl SM,Wen J,Moutsopoulos N. TGF-beta: amobile purveyor of immune privilege. Immunol Rev 2006; 213:213-227.
36. Fukuda N, HuWY, Kubo A, Kishioka H, Satoh C, SomaM, et al. Angiotensin II upregulates transforming growth factor-beta type I receptor on rat vascular smooth muscle cells. Am J Hypertens 2000; 13:191-198.
37. Henderson EL, Geng YJ, Sukhova GK, Whittemore AD, Knox J, Libby P. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation 1999; 99:96-104.
38. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182:1777-1783.
39. Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor- gamma activity. Circulation 2004; 109:2054-2057.
40. Marx N, Duez H, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004; 94:1168-1178.
41. Clemenz M, Frost N, Schupp M, Caron S, Foryst-Ludwig A, Bohm C, et al. Liver-speci?c ppar{alpha}-target gene regulation by the angiotensin type 1 receptor blocker telmisartan. Diabetes 2008; 57:1405-1413.
42. Staels B, KoenigW, Habib A, Merval R, Lebret M, Torra IP, et al. Activation of human aortic smooth-muscle cells is inhibited by PPARa but not by PPARg activators. Nature 1998; 393:790-793.
43. Takai S, Jin D, Muramatsu M, Yoshikawa K, Miyazaki M. Signi?cance of a lipophilic angiotensin II receptor blocker in a protective effect against vascular remodeling: comparison of telmisartan versus losartan [abstract]. J Hypertens 2005; 23(Suppl 2):S52.
44. Jones GT, Thompson AR, van Bockxmeer FM, Hafez H, Cooper JA, Golledge J, et al. Angiotensin II type 1 receptor 1166C polymorphism is associated with abdominal aortic aneurysm in three independent cohorts. Arterioscler Thromb Vasc Biol 2008; 28:764-770.